STING MARK Universal Fiducial Marker System
NCT: NCT05465161 · RECRUITING
Brief Summary
Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.
Frequently Asked Questions
What is STING MARK Universal Fiducial Marker System?
STING MARK Universal Fiducial Marker System is a clinical trial registered under NCT05465161. Current status: RECRUITING.
What is the status of NCT05465161?
The current status of NCT05465161 (STING MARK Universal Fiducial Marker System) is: RECRUITING.
When did STING MARK Universal Fiducial Marker System start?
STING MARK Universal Fiducial Marker System started on 2022-02-28.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.